Isoniazid: Essential Guide For Tuberculosis Treatment
Comprehensive guide to isoniazid for tuberculosis management, covering uses, dosing, risks, and patient advice for safe therapy.
Isoniazid, commonly known as INH, stands as a cornerstone in the fight against tuberculosis (TB), a bacterial infection primarily affecting the lungs caused by Mycobacterium tuberculosis. This medication effectively targets both active disease and latent infections, helping prevent progression and transmission. Approved for use alone or in multidrug regimens, isoniazid has been vital in global TB control efforts, listed by the World Health Organization as an essential medicine.
Understanding Tuberculosis and Isoniazid’s Vital Role
Tuberculosis remains a major global health threat, with millions of cases annually. Latent TB, where bacteria lie dormant without symptoms, affects up to a quarter of the world’s population and can reactivate years later, especially in vulnerable groups like those with HIV or weakened immunity. Isoniazid addresses this by killing susceptible bacteria, reducing reactivation risk by over 90% in preventive therapy.
In active TB cases, isoniazid forms the backbone of standard regimens, typically combined with rifampin, pyrazinamide, and ethambutol for the initial intensive phase. This four-drug approach combats resistance and ensures bacterial clearance, often spanning 6 to 9 months. For high-risk individuals—such as close contacts of TB patients, those with positive skin tests (Mantoux >5-10 mm depending on risk), or people with silicosis—preventive isoniazid monotherapy is recommended for 6-12 months.
Pharmacology: How Isoniazid Targets TB Bacteria
Isoniazid functions as a prodrug, requiring activation inside the bacteria by the enzyme KatG (catalase-peroxidase). Once activated, it forms reactive species that disrupt mycolic acid synthesis, a critical component of the mycobacterial cell wall. This leads to cell wall breakdown, making isoniazid bactericidal against rapidly dividing bacteria but bacteriostatic against slower-growing ones.
The drug also inhibits the cytochrome P450 system and acts as a mild monoamine oxidase inhibitor, though these effects are secondary to its primary antitubercular action. Resistance arises from mutations in genes like katG, inhA, or ahpC, underscoring the need for susceptibility testing before treatment.
Available Forms and Precise Dosing Protocols
Isoniazid is versatile, offered as oral tablets, syrup, and intramuscular injections, allowing flexibility for patients unable to swallow pills. Accurate dosing is crucial; for liquid forms, use a marked measuring device rather than household spoons to avoid under- or overdosing.
Dosage varies by indication, age, and regimen:
| Indication | Adults/Teens | Children | Frequency |
|---|---|---|---|
| Latent TB Prevention | 300 mg daily | 10 mg/kg (max 300 mg) daily | Once daily |
| Active TB Treatment (Daily) | 300 mg daily | 10-15 mg/kg (max 300 mg) daily | Once daily |
| Active TB (Intermittent) | 15 mg/kg (max 900 mg), 2-3x/week | 20-40 mg/kg (max 900 mg), 2-3x/week | 2-3 times/week |
Intermittent dosing suits directly observed therapy (DOT) programs, enhancing adherence. Treatment duration for active TB often involves 2 months intensive phase followed by 4 months continuation. Adjustments are needed for liver impairment or slow acetylators, who metabolize the drug slower.
Critical Safety Monitoring and Side Effect Management
While effective, isoniazid carries risks, notably hepatotoxicity, which can be severe or fatal, occurring in 0.1-1% of users and rising with age over 50, alcohol use, or chronic liver conditions. Monthly liver function tests (ALT/AST) are advised, with immediate discontinuation if levels exceed 3-5 times upper normal or symptoms like jaundice, fatigue, or nausea appear.
- Peripheral Neuropathy: Affects up to 20% at high doses (>6 mg/kg); prevented by pyridoxine (vitamin B6) 10-50 mg daily, as isoniazid depletes active B6 forms.
- Gastrointestinal Issues: Nausea, vomiting common; take with food if tolerated.
- Hematologic Effects: Rare aplastic anemia, thrombocytopenia; monitor blood counts if symptoms arise.
- Hypersensitivity: Rash, fever; stop drug and seek care.
- Other: Optic neuritis, gynecomastia, psychosis at overdose.
Overdose manifests rapidly with seizures, coma, acidosis; antidotes include pyridoxine (equal gram dose to ingested INH) and supportive care.
Drug Interactions and Lifestyle Considerations
Isoniazid interacts with several medications, potentiating toxicity:
- Alcohol: Heightens liver risk; abstain during therapy.
- Antiepileptics (phenytoin): Inhibits metabolism, raising levels.
- Rifampin: Combined use standard but monitor liver.
- Tyramine-rich foods: Mild MAO inhibition may cause hypertension.
Pregnant or breastfeeding individuals should use under supervision; it’s category A in pregnancy with no proven fetal risk. Patients with slow acetylation (common in some ethnic groups) may need dose tweaks based on genetic testing.
Patient Guidance for Optimal Outcomes
Adherence is paramount; missing doses risks resistance. DOT programs, where healthcare workers observe intake, boost success rates to 95%. Inform patients to report yellowing skin/eyes, dark urine, numbness, or persistent vomiting immediately. Complete full course—even if symptoms resolve early—to eradicate bacteria fully.
Store at room temperature, protect syrup from light. For injections, intramuscular sites rotate to prevent irritation.
Special Populations: Pediatrics, Elderly, and High-Risk Groups
In children, weight-based dosing ensures efficacy without excess toxicity. HIV-positive patients benefit greatly from preventive therapy, with adjusted skin test thresholds. Elderly face higher hepatotoxicity; baseline liver checks and B6 supplementation are routine. For renal impairment, no adjustment needed unless severe.
Global Impact and Resistance Challenges
Isoniazid’s inclusion in WHO essential medicines underscores its role in shortening regimens and curbing multidrug-resistant TB (MDR-TB). However, resistance, now at 10-20% in some regions, demands rapid diagnostics and alternative regimens like bedaquiline for failures. Ongoing research explores shorter courses and novel combinations.
Frequently Asked Questions (FAQs)
What if I miss a dose of isoniazid?
Take as soon as remembered unless near next dose; do not double up. Contact your doctor for guidance.
Can I drink alcohol while on isoniazid?
No—alcohol significantly increases liver damage risk. Avoid completely during treatment.
How long does TB treatment with isoniazid last?
Typically 6-9 months for active TB; 3-9 months for latent.
Does isoniazid cause weight gain or other common issues?
Not typically; main concerns are nerve issues (prevented by B6) and stomach upset.
Is isoniazid safe for pregnant women?
Yes, considered safe; benefits outweigh risks in TB exposure.
References
- Isoniazid (oral route, intramuscular route) — Mayo Clinic. 2023-10-01. https://www.mayoclinic.org/drugs-supplements/isoniazid-oral-route-intramuscular-route/description/drg-20064419
- Isoniazid — Wikipedia (citing primary sources). 2024-01-15. https://en.wikipedia.org/wiki/Isoniazid
- Isoniazid: MedlinePlus Drug Information — MedlinePlus (NIH). 2023-05-15. https://medlineplus.gov/druginfo/meds/a682401.html
- Isoniazid: Uses, Interactions, Mechanism of Action — DrugBank. 2024-02-10. https://go.drugbank.com/drugs/DB00951
- Isoniazid Tablets, USP Label — FDA. 2016-08-01. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/008678s028lbl.pdf
Similar Articles
Read full bio of Sneha Tete
